Augustine Therapeutics

Executive Summary

Augustine Therapeutics is a preclinical biotechnology company focused on developing small molecule therapies for neurodegenerative diseases, including Alzheimer's disease and ALS. Founded in 2020 and headquartered in New York, the company targets novel pathways involved in neuronal stress and survival to create disease-modifying treatments. With $84.8 million raised to date, Augustine is well-capitalized to advance its lead programs toward clinical development, addressing the high unmet need in neuroscience where many late-stage trials have historically failed. The company's platform aims to tackle fundamental mechanisms of neurodegeneration, offering potential first-in-class or best-in-class candidates.

Upcoming Catalysts (preview)

• H2 2026IND Submission for Lead Candidate65% success
• 2026Series B Financing80% success
• H1 2026Preclinical Data Presentation at Major Conference90% success